The molecular docking study was based on ligands with demonstrated biological action in the scientific literature (i.e., ripasudil and fasudil) and targeting key proteins (i.e., ROCK1 and ROCK2) identified as being involved in the modulation of glaucoma pathophysiological mechanisms. The gene discussed is ROCK2; the disease is glaucoma.